Navigation Links
Parkinson's Disease Foundation announces award of $150,000
Date:10/23/2008

(October 23, 2008, New York, NY) The Parkinson's Disease Foundation (PDF) is pleased to announce an award of $150,000 toward investigations studying the potential of individualized stem cell therapy to treat Parkinson's disease (PD).

The grant will support the research of Marina Emborg, M.D., Ph.D., and Su-Chun Zhang, M.D., Ph.D., both of the University of Wisconsin, Madison. This award was chosen as part of PDF's mission to fund scientific research that has great potential to increase our understanding of Parkinson's and to find treatments and a cure.

Dr. Emborg and Dr. Zhang will be conducting a pilot study that examines the use of transformed adult skin cells in the treatment of Parkinson's. Scientists can now direct the skin cells of a person with Parkinson's to become pluripotent stem cells (iPS), which appear to have similar potential to embryonic stem cells. This means that iPS cells can change into any other type of cell in the body, including dopamine neurons the very cells that are damaged in the brains of people with Parkinson's. Scientists theorize that transplanting replacement cells in the brains of people with Parkinson's could ease symptoms of the disease. Though technical challenges lay ahead with the iPS method, its discovery has allowed researchers to sidestep ethical and political debates associated with using embryonic stem cells.

Dr. Zhang's laboratory will examine the potential of iPS cells by reverting skin cells of Rhesus monkeys into iPS cells and directing the cells to become dopamine neurons. Next, Dr. Emborg and her colleagues will insert the dopamine neurons produced by Dr. Zhang's team into the brains of the same animals that donated the skin cells animals who, through use of a compound called MPTP, have a condition much like Parkinson's disease. Dr. Emborg will observe how well these cells survive and integrate in the brain and she will measure the cells' effect on the health of the monkeys. For example, she will monitor the animals for the development of tumors or immune reactions, as well as changes in their parkinsonian signs.

Dr. Zhang and Dr. Emborg hope that implanting the transformed cells back into the monkeys from whom they were originally taken will replace the dopamine neurons missing and damaged by Parkinson's disease. Dr. Emborg says that while their investigations are in early stages, if successful, they would bring us closer to developing a, "personalized regenerative therapy" for Parkinson's disease. One benefit to 'personalized' cell treatment is that it would avoid the issue of immune rejection that can be found with other stem cell therapies.

Dr. Emborg noted, "With funding from PDF, we can conduct preliminary investigations that should illuminate the potential of an exciting concept: treating people with Parkinson's with their very own cells."

Robin Anthony Elliott, Executive Director of the Parkinson's Disease Foundation, said, "PDF is pleased to support the research of Dr. Emborg and Dr. Zhang. This project reaffirms PDF's commitment to funding research of the highest caliber that may help us to understand and treat Parkinson's."

This grant is part of PDF's four-pronged approach to funding Parkinson science. PDF's traditional research initiatives include a Center Grants Program, which funds research at three leading universities; the International Research Grants Program, which provides seed grants to promising scientists studying the science of PD; career development and fellowship programs that support continued interest in the field of Parkinson's; and collaborative endeavors with other organizations that fund PD research. In fiscal year 2008, PDF contributed $5.5 million to support Parkinson's disease research.


'/>"/>

Contact: Melissa Barry
mbarry@pdf.org
212-923-4700
Parkinson's Disease Foundation
Source:Eurekalert

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. Gender, coupled with diabetes, affects vascular disease development
3. Study links cat disease to flame retardants in furniture and to pet food
4. Humans fostering forest-destroying disease
5. Emerging (disease) markets
6. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
7. Clemson chemists discover new way antioxidants fight debilitating diseases
8. Finding that 1-in-a-billion that could lead to disease
9. Study shows link between alcohol consumption and hiv disease progression
10. Natural chemical found in broccoli helps combat skin blistering disease
11. 60 second test could help early diagnosis of common brain diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
Breaking Biology Technology: